JustinPFavaroMD

Oncology • Charlotte, NC

Physician

Join to view full profile

Dr. Favaro is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Favaro's full profile

Already have an account?

Office
2711 Randolph Rd
Suite 400
Charlotte, NC 28207
Phone+1 704-342-1900

Fax+1 704-377-0353
Is this information wrong?

Education & Training

University of Texas Southwestern Medical CenterResidency, Internal Medicine, 2000 - 2003
Medical University of South CarolinaClass of 2000

Certifications & Licensure

SC State Medical License 2022 - 2025
NC State Medical License 2003 - 2024
TX State Medical License 2002 - 2004
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2013

Clinical Trials

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
Completed
Phase 3
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer Start of enrollment: 2011 Nov 01
Completed
Not Applicable
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Start of enrollment: 2011 Feb 14
Completed
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
S0820, Adenoma and Second Primary Prevention Trial Start of enrollment: 2013 Aug 23
Active, not recruiting
Phase 3
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer Start of enrollment: 2012 Jul 01
Completed
Phase 2
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery Start of enrollment: 2013 Aug 01
Active, not recruiting
Not Applicable
A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib Start of enrollment: 2014 Jun 04
Completed
Phase 2
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) Start of enrollment: 2015 Feb 11
Active, not recruiting
Phase 3
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE) Start of enrollment: 2015 May 01
Completed
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

12 citations
Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis.
P Ryan, Ali McBride, David Ray, S Pulgar, Robert A. Ramirez, Emad Elquza, J P Favaro, G Dranitsaris> ;Journal of Oncology Pharmacy Practice. 2019 Mar 29
30 citations
A Phase II Study of Capecitabine, Oxaliplatin, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas
Hope E. Uronis, Johanna C. Bendell, Ivy Altomare, Gerard C. Blobe, S. David Hsu, Michael A. Morse, Herbert Pang, S. Yousuf Zafar, Paul Conkling, Justin Favaro, Christy...> ;The Oncologist. 2013 Mar 1
59 citations
Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing
Christina I. Herold, Vijaya Chadaram, Bercedis L. Peterson, P. Kelly Marcom, Judith O. Hopkins, Gretchen Kimmick, Justin Favaro, Erika Hamilton, Renee Welch, Sarah S. ...> ;Clinical Cancer Research. 2011 Sep 15
3 citations
A Phase I Dose-Escalation Study of Imatinib Mesylate (Gleevec/STI571) plus Capecitabine (Xeloda) in Advanced Solid Tumors
Elizabeth Dugan, Roxanne Truax, Kellen L. Meadows, Andrew B. Nixon, William P. Petros, Justin Favaro, N. Fernando, Michael A. Morse, Gerard C. Blobe, Herbert Hurwitz> ;Anticancer Research. 2010 Apr 1
14 citations
Long-Term Treatment with Bevacizumab for Patients with Metastatic Colorectal Cancer: Case Report
Herbert Hurwitz, Wanda Honeycutt, Sherri Haley, Justin Favaro> ;Clinical Colorectal Cancer. 2006 May 1
10 citations
Targeted therapy in renal cell carcinoma.
Justin Favaro, Daniel J. George> ;Expert Opinion on Investigational Drugs. 2005 Sep 27
10 citations
Effect of Rev on the Cytoplasmic Localization of Intron-Containing Human Immunodeficiency Virus Type 1 RNA
Justin P. Favaro, Frank Maldarelli, Salvatore J. Arrigo, Michael G. Schmidt> ;Virology. 1999 Mar 15
4 citations
Activation of a Cryptic Splice Donor in Human Immunodeficiency Virus Type-1
Keith M. Borg, Justin P. Favaro, Salvatore J. Arrigo, Michael G. Schmidt> ;Journal of Biomedical Science. 1999 Jan 1
12 citations
Effect of Rev on the intranuclear localization of HIV-1 unspliced RNA.
Justin P. Favaro, Keith T. Borg, Salvatore J. Arrigo, Michael G. Schmidt> ;Virology. 1998 Sep 30
10 citations
Involvement of human immunodeficiency virus type-1 splice sites in the cytoplasmic accumulation of viral RNA.
Keith T. Borg, Justin P. Favaro, Salvatore J. Arrigo> ;Virology. 1997 Sep 15
13 citations
Characterization of Rev Function Using Subgenomic and Genomic Constructs in T and COS Cells
Justin P. Favaro, Salvatore J. Arrigo> ;Virology. 1997 Feb 3
155 citations
Retrovirus-mediated transfer of viral IL-10 gene prolongs murine cardiac allograft survival
Lihui Qin, Kenneth D. Chavin, Yaozhong Ding, Hideaki Tahara, Justin P. Favaro, Jennifer E. Woodward, Tadamichi Suzuki, Paul D. Robbins, Michael T. Lotze, Jonathan S. B...> ;Journal of Immunology. 1996 Mar 15
111 citations
Multiple vectors effectively achieve gene transfer in a murine cardiac transplantation model. Immunosuppression with TGF-beta 1 or vIL-10.
Lihui Qin, Kenneth D. Chavin, Y Ding, Justin P. Favaro, Jennifer E. Woodward, Jixun Lin, Hideaki Tahara, Paul D. Robbins, Abraham Shaked, Dora Y. Ho> ;Transplantation. 1995 Mar 27
52 citations
Gene transfer for transplantation. Prolongation of allograft survival with transforming growth factor-beta 1.
Lihui Qin, Kenneth D. Chavin, Yaozhong Ding, Jennifer E. Woodward, Justin P. Favaro, Jixun Lin, Jonathan S. Bromberg> ;Annals of Surgery. 1994 Oct 1
Join now to see all

Press Mentions

Three Years After COVID-19 Pandemic Began in N.C., Doctor Says Increased Hygiene, Telehealth Here to StayMarch 8th, 2023
Featured Practice: Oncology Specialists of CharlotteJune 18th, 2021
Cancer Centers Suffer from a Major Shortage of Popular Chemotherapy DrugsJune 22nd, 2023
Join now to see all